152 related articles for article (PubMed ID: 16996123)
1. Effects of the CB1R agonist WIN-55,212-2 and the CB1R antagonists SR-141716 and AM-1387: open-field examination in rats.
Järbe TU; Ross T; DiPatrizio NV; Pandarinathan L; Makriyannis A
Pharmacol Biochem Behav; 2006 Sep; 85(1):243-52. PubMed ID: 16996123
[TBL] [Abstract][Full Text] [Related]
2. Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats.
Järbe TU; LeMay BJ; Olszewska T; Vemuri VK; Wood JT; Makriyannis A
Pharmacol Biochem Behav; 2008 Nov; 91(1):84-90. PubMed ID: 18640150
[TBL] [Abstract][Full Text] [Related]
3. Effects of AM1346, a high-affinity CB1 receptor selective anandamide analog, on open-field behavior in rats.
Järbe TU; DiPatrizio NV; Li C; Makriyannis A
Behav Pharmacol; 2007 Nov; 18(7):673-80. PubMed ID: 17912052
[TBL] [Abstract][Full Text] [Related]
4. The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist (R)-methanandamide in rats.
Järbe TU; DiPatrizio NV; Li C; Makriyannis A
Pharmacol Biochem Behav; 2003 Jul; 75(4):809-21. PubMed ID: 12957223
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid type 1 receptor ligands WIN 55,212-2 and AM 251 alter anxiety-like behaviors of marmoset monkeys in an open-field test.
Cagni P; Barros M
Behav Brain Res; 2013 Mar; 240():91-4. PubMed ID: 23183218
[TBL] [Abstract][Full Text] [Related]
6. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
7. (-)-Adamantyl-delta8-tetrahydrocannabinol (AM-411), a selective cannabinoid CB1 receptor agonist: effects on open-field behaviors and antagonism by SR-141716 in rats.
Järbe TU; DiPatrizio NV; Lu D; Makriyannis A
Behav Pharmacol; 2004 Nov; 15(7):517-21. PubMed ID: 15472574
[TBL] [Abstract][Full Text] [Related]
8. Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited.
Järbe TU; Andrzejewski ME; DiPatrizio NV
Pharmacol Biochem Behav; 2002 Nov; 73(4):911-9. PubMed ID: 12213538
[TBL] [Abstract][Full Text] [Related]
9. Suppression of outward K⁺ currents by WIN55212-2 in rat retinal ganglion cells is independent of CB1/CB2 receptors.
Zhang CQ; Wu HJ; Wang SY; Yin S; Lu XJ; Miao Y; Wang XH; Yang XL; Wang Z
Neuroscience; 2013 Dec; 253():183-93. PubMed ID: 24013008
[TBL] [Abstract][Full Text] [Related]
10. Antagonism between the anti-inflammatory activity of the cannabinoid WIN 55212-2 and SR 141716A.
Pozzi O; Misiano P; Clark GD; Visentin L
Pharmacology; 2003 Nov; 69(3):158-63. PubMed ID: 14512703
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid type-1 receptor ligands, alone or in combination with cocaine, affect vigilance-related behaviors of marmoset monkeys.
Cagni P; Melo GC; de Jesus AG; Barros M
Brain Res; 2014 Mar; 1550():27-35. PubMed ID: 24445195
[TBL] [Abstract][Full Text] [Related]
12. Effects of SR141716 and WIN 55,212-2 on tolerance to ethanol in rats using the acute and rapid procedures.
Lemos JI; Takahashi RN; Morato GS
Psychopharmacology (Berl); 2007 Oct; 194(2):139-49. PubMed ID: 17546513
[TBL] [Abstract][Full Text] [Related]
13. Differentiation between low- and high-efficacy CB1 receptor agonists using a drug discrimination protocol for rats.
Järbe TU; LeMay BJ; Halikhedkar A; Wood J; Vadivel SK; Zvonok A; Makriyannis A
Psychopharmacology (Berl); 2014 Feb; 231(3):489-500. PubMed ID: 24005529
[TBL] [Abstract][Full Text] [Related]
14. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
[TBL] [Abstract][Full Text] [Related]
15. WIN-55,212-2 and SR-141716A alter nicotine-induced changes in locomotor activity, but do not alter nicotine-evoked [3H]dopamine release.
Rodvelt KR; Bumgarner DM; Putnam WC; Miller DK
Life Sci; 2007 Jan; 80(4):337-44. PubMed ID: 17067637
[TBL] [Abstract][Full Text] [Related]
16. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2.
Darmani NA
Eur J Pharmacol; 2001 Oct; 430(1):49-58. PubMed ID: 11698062
[TBL] [Abstract][Full Text] [Related]
17. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A.
Gifford AN; Ashby CR
J Pharmacol Exp Ther; 1996 Jun; 277(3):1431-6. PubMed ID: 8667207
[TBL] [Abstract][Full Text] [Related]
18. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents.
Haller J; Varga B; Ledent C; Freund TF
Behav Pharmacol; 2004 Jul; 15(4):299-304. PubMed ID: 15252281
[TBL] [Abstract][Full Text] [Related]
19. The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.
Maneuf YP; Crossman AR; Brotchie JM
Exp Neurol; 1997 Nov; 148(1):265-70. PubMed ID: 9398468
[TBL] [Abstract][Full Text] [Related]
20. Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats.
Järbe TU; Liu Q; Makriyannis A
Psychopharmacology (Berl); 2006 Jan; 184(1):36-45. PubMed ID: 16307294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
